MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Near-term catalysts center on the imminent Q4 2026 unblinded 12-week MAD data for MBX 4291 and ObesityWeek 2026 preclinical presentations, offset by a wider-than-expected Q3 loss; net short-term bias is cautiously positive but event-driven and volatile.
MBX confirmed the unblinded 12-week multiple ascending dose (Part C, Cohort 1) data for obesity candidate MBX 4291 remains on track for Q4 2026. This is the key near-term binary catalyst to confirm durability of the ~7% weight loss seen at 8 weeks and the tolerability profile; strong data could drive a sharp re-rating, weak data a selloff.
MBX Biosciences Press Release (GlobeNewswire)MBX will present preclinical pharmacokinetic data for MBX 6180, a once-monthly GLP-1/GIP/GCG triple agonist prodrug, at ObesityWeek 2026 (Nov 14-17, Washington D.C.). Positive preclinical exposure could reinforce the platform narrative and support sentiment into the event.
MBX Biosciences Press Release (GlobeNewswire)MBX reported Q3 2026 EPS of -$1.29 versus consensus -$0.80, with net loss widening to $62.4M (including $20.8M stock comp tied to former CEO award modification) and R&D up to $32.0M on Phase 3 start-up costs. Cash of $481.6M funds operations into 2029, limiting financing overhang, but the headline miss may weigh on near-term sentiment.
MBX Biosciences Press Release (GlobeNewswire)Stifel lifted its price target to $84 from $70 (Buy), citing the upcoming Part C readout and framing 6-8% weight loss as competitive, with ~10% plus better tolerability potentially pushing shares above $80. The note anchors bullish expectations ahead of the data and may amplify the reaction to the readout.
Investing.comAt the Guggenheim Healthcare Innovation Conference, management cautioned investors not to "get over your skis" on the early 7% weight loss (only 8 subjects, 6 active) and noted the obesity franchise may need outside capital and partners. This tempered framing could cap upside enthusiasm ahead of the Q4 readout.
Investing.com